Technical Analysis for AGN - Allergan, Inc.
|Grade||Last Price||% Change||Price Change|
AGN closed up 1.69 percent on Friday, February 23, 2018, on 86 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|See historical AGN trend table...|
|Date||Alert Name||Type||% Chg|
|Feb 23||Narrow Range Bar||Range Contraction||0.00%|
|Feb 23||NR7||Range Contraction||0.00%|
|Feb 23||NR7-2||Range Contraction||0.00%|
|Feb 23||Wide Bands||Range Expansion||0.00%|
|Feb 22||Narrow Range Bar||Range Contraction||1.69%|
|Feb 22||NR7||Range Contraction||1.69%|
|Feb 22||NR7-2||Range Contraction||1.69%|
|Feb 22||Multiple of Ten Bearish||Other||1.69%|
|Feb 22||Wide Bands||Range Expansion||1.69%|
|Feb 22||Oversold Stochastic||Weakness||1.69%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
- Earnings date: 2018-02-06
Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and over-the-counter skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. It focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, urologists, and general practitioners. The company has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more AGN news...
|52 Week High||254.9867|
|52 Week Low||156.0|
|200-Day Moving Average||203.7931|
|50-Day Moving Average||171.6616|
|20-Day Moving Average||168.916|
|10-Day Moving Average||162.048|
|Average True Range||5.2116|
|Chandelier Exit (Long, 3 ATRs )||174.3052|
|Chandelier Exit (Short, 3 ATRs )||171.6348|
|Upper Bollinger Band||187.3922|
|Lower Bollinger Band||150.4398|
|Percent B (%b)||0.32|
|MACD Signal Line||-3.4319|
|Market Cap||54.19 Billion|
|Num Shares||334 Million|
|Price-to-Earnings (P/E) Ratio||4.94|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||165.86|
|Resistance 3 (R3)||165.59||164.08||165.23|
|Resistance 2 (R2)||164.08||163.12||164.21||165.02|
|Resistance 1 (R1)||163.08||162.53||163.58||163.35||164.81|
|Support 1 (S1)||160.57||160.61||161.07||160.84||159.37|
|Support 2 (S2)||159.06||160.02||159.19||159.16|
|Support 3 (S3)||158.06||159.06||158.95|
|Support 4 (S4)||158.33|